Utah State researchers advance CRISPR for cancer treatment

Utah State biochemists demonstrated Cas12a2, a CRISPR variant programmable to selectively destroy cancer cells while preserving healthy tissue. Unlike standard Cas9 approaches, Cas12a2 offers enhanced targeting precision, advancing the case for gene-editing as a viable oncology therapeutic modality.